4.1 Article Data Paper

The capture proteasome assay (CAPA) to evaluate subtype-specific proteasome inhibitors

Journal

DATA IN BRIEF
Volume 4, Issue -, Pages 146-151

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.dib.2015.04.019

Keywords

Proteasome; Activity assay; Fluorogenic peptides; Proteasome-Glo

Funding

  1. Belgian Program on Interuniversity Poles of Attraction
  2. Belgian State (Prime Minister's Office, Science Policy Programming)
  3. Fonds National de la Recherche Scientifique (Televie) [7454313F]
  4. Fonds National de la Recherche Scientifique (F.R.S.M.) [T.0022.14]
  5. Fondation contre le Cancer (nonprofit organization, Belgium)
  6. Fonds J. Maisin (Belgium)
  7. Fondation Salus Sanguinis (Belgium)
  8. Ludwig Institute for Cancer Research
  9. WELBIO
  10. Fonds National de la Recherche Scientifique (F.R.S.-FNRS, Belgium)

Ask authors/readers for more resources

We recently developed a new assay to measure proteasome activity in vitro (CAPA for capture proteasome assay) [1] based on proteasome capture on an antibody -coated plate. When used with lysates originating from cells expressing either standard proteasome, immunoproteasome or intermediate proteasomes beta 5i or beta 1i-beta 5i, this assay allows the individual monitoring of the chymotrypsin-like, trypsin-like and caspase-like activities of the corresponding proteasome subtypes. The efficiency and specificity of four proteasome inhibitors were studied using the CAPA assay, demonstrating the potential of this assay for the development of subtype-specific proteasome inhibitors. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available